by jtcir-auto | Nov 6, 2020 | Press Releases
– Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021- Continue to advance discussions to secure a commercialization partner for macimorelin in Europe and other key global markets- Ongoing evaluations...
by jtcir-auto | Sep 16, 2020 | Press Releases
– Recently secured funding bolsters cash runway to fund operations and provides significant optionality for growth- Pivotal Phase 3 safety and efficacy study AEZS-130-P02 (“Study P02”) expected to commence in Q1 2021-Ongoing evaluations to expand...
by jtcir-auto | Sep 9, 2020 | Press Releases
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT – CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty...
by jtcir-auto | Sep 9, 2020 | Press Releases
– Live video webcast with CEO, Dr. Klaus Paulini, on Wednesday, September 16th at 11:00 AM EDT – CHARLESTON, S.C., Sept. 09, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the “Company”), a specialty...
by jtcir-auto | Sep 8, 2020 | Press Releases
– PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults — Data from this study support the choice of 1.0 mg/kg dose of macimorelin for validity testing in a Phase 3 trial, expected...
by jtcir-auto | Sep 8, 2020 | Press Releases
– PK and PD profiles of macimorelin for pediatric use were within the expected range and comparable to results observed in adults — Data from this study support the choice of 1.0 mg/kg dose of macimorelin for validity testing in a Phase 3 trial, expected...